A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
This study has been terminated.
(The study was terminated early due to insufficient evidence of clinical benefit.)
First Posted: December 5, 2007
Last Update Posted: May 9, 2016
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )